Clinical Trial: Limertinib Plus Radiotherapy for EGFR-Mutant NSCLC With Brain Metastases

U.S., Feb. 18 -- ClinicalTrials.gov registry received information related to the study (NCT07413952) titled 'Limertinib Plus Radiotherapy for EGFR-Mutant NSCLC With Brain Metastases' on Feb. 10.

Brief Summary: Patients with epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC) with brain metastases remain a major clinical challenge. Although EGFR-TKIs have demonstrated intracranial activity, disease control is still suboptimal in some patients.

Limertinib (ASK120067) is a novel third-generation EGFR tyrosine kinase inhibitor with favorable central nervous system penetration and encouraging intracranial antitumor activity. The potential synergistic effect of limertinib combined with radiotherapy warrants further...